Treating to target in rheumatoid arthritis: biologic therapies.

about

Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

P2860

Q37689754-301223AC-556A-48C5-8096-91643746EDEF

P2860

Treating to target in rheumatoid arthritis: biologic therapies.

Item

http://www.wikidata.org/entity/Q37954077

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Treating to target in rheumatoid arthritis: biologic therapies.

@en

Treating to target in rheumatoid arthritis: biologic therapies.

@nl

type

Item

label

Treating to target in rheumatoid arthritis: biologic therapies.

@en

Treating to target in rheumatoid arthritis: biologic therapies.

@nl

prefLabel

Treating to target in rheumatoid arthritis: biologic therapies.

@en

Treating to target in rheumatoid arthritis: biologic therapies.

@nl

P1476

Treating to target in rheumatoid arthritis: biologic therapies.

@en

P2093

Jill Firth

http://www.w3.org/2001/XMLSchema#string

Sarah Critchley

http://www.w3.org/2001/XMLSchema#string

P2860

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Treating rheumatoid arthritis to target: recommendations of an international task force.

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis.

Rheumatoid arthritis: treating to target with disease-modifying drugs.

Biological nurse specialist: goodwill to good practice.

Sulfasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases.

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

P304

1284, 1287-8, 1290-1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12968/BJON.2011.20.20.1284

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22068002

http://www.w3.org/2001/XMLSchema#string

Treating to target in rheumatoid arthritis: biologic therapies.

about

P2860

P2860

Treating to target in rheumatoid arthritis: biologic therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698